SYK Stock Recent News

Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2024:

Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) announced today that Glenn S. Boehnlein will retire from his role as Vice President, Chief Financial Officer. Boehnlein's decision follows an impressive 22-year career at Stryker. Preston Wells, who currently serves as Group CFO for Stryker's Orthopaedics Group, will assume the role of Vice President, Chief Financial Officer effective April 1, 2025.

SYK's fourth-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.

Stryker Corporation is a high-quality, innovative medical device company with a strong history of revenue, earnings, and FCF growth, driven by R&D and M&A strategies. Shares are currently expensive with a PEG ratio around 3, but the company's consistent performance and market leadership justify a premium valuation. Stryker's strong company culture, impressive ROIC, and substantial insider ownership indicate a durable competitive advantage and a bright future.

Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?

Beyond analysts' top -and-bottom-line estimates for Stryker (SYK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.

Portage, Michigan, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) today announced that it is commencing, through a wholly owned subsidiary, Eagle 1 Merger Sub, Inc., a cash tender offer to purchase all of the issued and outstanding shares of common stock of Inari Medical, Inc. (NASDAQ: NARI) for $80.00 per share in cash. The offer is being made pursuant to the previously announced merger agreement, dated as of January 6, 2025, among Stryker, Eagle 1 Merger Sub, Inc and Inari.

Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inari Medical, Inc. (NasdaqGS: NARI) to Stryker (NYSE: SYK). Under the terms of the proposed transaction, shareholders of Inari will receive $80.00 in cash for each share of Inari that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the c.

SYK inks an agreement to acquire Inari Medical at a valuation of approximately $4.9 billion.